Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Harmony Biosciences Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jeffrey Dayno

İcra Kurulu Başkanı

US$4.5m

Toplam tazminat

CEO maaş yüzdesi	13.8%
CEO görev süresi	1.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	4.2yrs

Son yönetim güncellemeleri

Recent updates

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 03

These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Apr 04

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Feb 09

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Mar 21

Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Dec 01

Harmony Biosciences: In Harmony

Sep 23

We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Aug 05

Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M

Aug 02

Harmony Biosciences: Steady Revenue Generator Looking For A Future

May 26

Harmony Biosciences: Strong Growth At A Reasonable Price

Mar 04

Our First Look At Harmony Biosciences

Nov 04

CEO Tazminat Analizi

Jeffrey Dayno'un ücretlendirmesi Harmony Biosciences Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$115m
Mar 31 2024	n/a	n/a	US$138m
Dec 31 2023	US$4m	US$613k	US$129m
Sep 30 2023	n/a	n/a	US$151m
Jun 30 2023	n/a	n/a	US$200m
Mar 31 2023	n/a	n/a	US$189m
Dec 31 2022	US$762k	US$459k	US$181m
Sep 30 2022	n/a	n/a	US$156m
Jun 30 2022	n/a	n/a	US$58m
Mar 31 2022	n/a	n/a	US$49m
Dec 31 2021	US$703k	US$446k	US$35m
Sep 30 2021	n/a	n/a	US$12m
Jun 30 2021	n/a	n/a	US$17m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$3m	US$431k	-US$64m
Sep 30 2020	n/a	n/a	-US$110m
Jun 30 2020	n/a	n/a	-US$146m
Mar 31 2020	n/a	n/a	-US$165m
Dec 31 2019	US$672k	US$414k	-US$187m

Tazminat ve Piyasa: Jeffrey 'ın toplam tazminatı ($USD 4.45M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.54M ).

Tazminat ve Kazançlar: Jeffrey şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Jeffrey Dayno (67 yo)

1.8yrs

Görev süresi

US$4,450,294

Tazminat

Dr. Jeffrey M. Dayno, M.D. serves as President, Chief Executive Officer and Director at Harmony Biosciences, LLC since 2023 and served as its Interim President and Chief Executive Officer since January 06,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffrey Aronin	Founder & Non-Executive Chairman	7yrs	US$185.67k	0.44% $ 8.8m
Jeffrey Dayno	President	1.8yrs	US$4.45m	Veri yok
Sandip Kapadia	Executive VP	3.6yrs	US$5.58m	0.012% $ 242.9k
Kumar Budur	Executive VP and Chief Medical & Scientific Officer	less than a year	US$760.81k	0.0018% $ 35.0k
Jeffrey Dierks	Executive VP & Chief Commercial Officer	6.3yrs	US$5.60m	0% $ 0
Andrew Serafin	Executive VP & Chief Strategy Officer	5.8yrs	US$647.43k	0% $ 0
David Bradshaw	Head of Technical Operations	no data	Veri yok	Veri yok
Brennan Doyle	VP & Head of Investor Relations	no data	Veri yok	Veri yok
Christian Ulrich	General Counsel & Corporate Secretary	3.8yrs	Veri yok	Veri yok
Tricia Glover	Chief Compliance Officer	3.4yrs	Veri yok	Veri yok
Audrey Murphy	Vice Presidet of Human Resources	no data	Veri yok	Veri yok
Cate McCanless	Head of Corporate Affairs & Public Policy	no data	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: HRMY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffrey Aronin	Founder & Non-Executive Chairman	7yrs	US$185.67k	0.44% $ 8.8m
Jeffrey Dayno	President	1.8yrs	US$4.45m	Veri yok
Andreas Wicki	Independent Director	7.1yrs	Veri yok	Veri yok
R. Graf	Independent Director	3.9yrs	US$179.99k	0% $ 0
Gary Sender	Independent Director	4.2yrs	US$303.00k	0% $ 0
Antonio Gracias	Independent Director	7.1yrs	US$235.00k	0% $ 0
Peter Anastasiou	Independent Director	less than a year	US$132.51k	Veri yok
Linda Szyper	Independent Director	2.9yrs	US$174.99k	0% $ 0
Juan Sabater	Independent Director	7.8yrs	US$179.99k	0% $ 0

4.2yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HRMY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).

Harmony Biosciences Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Harmony Biosciences Holdings, Inc., Annual General Meeting, May 29, 2024

Executive VP exercised options and sold US$269k worth of stock

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou as Class III Director and Member of the Compensation Committee of the Board

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou to its Board of Directors

Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Chief Medical Officer

Recent updates

Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Harmony Biosciences: Advancing An Expanded Pipeline

Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024

Harmony Biosciences Holdings, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet

Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration (FDA) Action Deny the Citized Petition for WAKIX®? (PITOLSIANT)

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX (Pitolisant) in Pediatric Patients with Narcolepsy

Harmony Biosciences Holdings, Inc. Reaffirms Sales Guidance for the Year 2024

Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1

Consensus EPS estimates fall by 21%

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations

Harmony Biosciences Holdings, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Harmony Biosciences Holdings, Inc., Annual General Meeting, May 29, 2024

These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Executive VP exercised options and sold US$269k worth of stock

Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Consensus EPS estimates fall by 11%

Full year 2023 earnings: EPS misses analyst expectations

U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® (pitolisant) in Pediatric Narcolepsy

Harmony Biosciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024

Harmony Biosciences Holdings, Inc. Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou as Class III Director and Member of the Compensation Committee of the Board

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou to its Board of Directors

Investor sentiment improves as stock rises 26%

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) announces an Equity Buyback for $200 million worth of its shares.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Harmony Biosciences Showcases the Newest Patients At the Heart and Progress At the Heart Award Recipients

Harmony Biosciences Holdings, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Harmony Biosciences Holdings, Inc. Announces Topline Data from Phase 3 Intune Study Evaluating Pitolisant in Patients with Idiopathic Hypersomnia

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 35%

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) announces an Equity Buyback for $125 million worth of its shares.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harmony Biosciences Holdings, Inc. Announces Plans to Initiate Phase 3 Registration Study of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences Holdings, Inc. Completes Enrollment of Phase 3 Registrational Intune Study in Idiopathic Hypersomnia

Harmony Biosciences Holdings, Inc. to Present New Wanix (Pitolisant) Safety and Efficacy Data

Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Chief Medical Officer

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.4% to US$59.89

Executive VP & CFO exercised options and sold US$514k worth of stock

Investor sentiment deteriorates as stock falls 27%

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Full year 2022 earnings: EPS exceeds analyst expectations

Harmony Biosciences Holdings, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Harmony Biosciences Holdings, Inc. Announces CEO Changes

Executive VP & Chief Strategy Officer exercised options and sold US$2.0m worth of stock

Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Consensus EPS estimates increase by 119%

Executive VP & Chief Medical Officer exercised options and sold US$703k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harmony Biosciences Holdings, Inc. Announces Topline Results from Phase 2 Proof-Of-Concept Study Evaluating Pitolisant for Excessive Daytime Sleepiness in Patients with Prader-Willi Syndrome

Harmony Biosciences Holdings, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Executive VP & Chief Commercial Officer exercised options and sold US$444k worth of stock

Harmony Biosciences: In Harmony

President exercised options and sold US$1.7m worth of stock

Consensus forecasts updated

We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M

Harmony Biosciences Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Investor sentiment improved over the past week

President exercised options and sold US$899k worth of stock